Kronik migrenli olgularda serum S100B ve nöron spesifik enolaz düzeylerine etki edan faktörler

Abstract

Amaç: Bu çalışmada kronik migreni olan hastalarda beyinde hücresel hasarı gösteren NSE ve S100B düzeylerinde artış olup olmadığı, artış var ise tedavi sonrası klinik iyileşme ile birlikte NSE ve S100B düzeylerinde başlangıca göre değişiklik olup olmadığını araştırmak amaçlanmıştır. Yöntem: X Üniversitesi Hastanesi Nöroloji Kliniği’ne başvuran kronik migren tanılı 30 kişi hasta grubuna ve 20 sağlıklı gönüllü kontrol grubuna dahil edildi. Kronik migreni olan hastalar amitriptilin 75 mg/gün dozunda 3 aylık tedavi aldı. Hasta ve kontrol gruplarında çalışma başlangıcında serum NSE ve S100 B düzeyleri ölçüldü. Hasta grubunda 3 aylık amitriptilin tedavisi sonrası tekrar serum NSE ve S100 B düzeyleri ölçüldü. Bulgular: Bu çalışmada kontrol grubu ile kronik migren hasta grubu arasında S100B ve NSE düzeylerinde istatistiksel olarak anlamlı bir fark bulunmamıştır. Kronik migren hasta grubunda tedavi öncesi ve sonrası serum S100B ve NSE düzeylerinde istatistiksel olarak anlamlı bir fark gözlenmemiştir (tümü p > 0,05). Ancak korelasyon analizi, tedavi öncesinde S100B ve NSE düzeylerinin zayıf, pozitif, anlamsız bir korelasyon gösterdiğini ortaya koymuştur (Spearman'ın ρ = 0,302, p = 0,104). Tedaviden sonra bu ilişki orta derecede pozitif ve istatistiksel olarak anlamlı hale gelmiştir (Spearman'ın ρ = 0,511, p = 0,004). Sonuç: Bu çalışmanın sonuçlarına göre nöronal hasar belirteçleri olduğuna inanılan S100B ve NSE'nin izlenmesinin, sağlıklı bireylerden farklı olarak kronik migren hastalarında tedavinin etkinliğini izlemede faydalı olabileceği düşünülmüştür.

Keywords

• Kronik Migren
• Nöron Spesifik Enolaz
• S100B
• tedavi yanıtı

Supporting Institution

Fırat Üniversitesi BAP

Ethical Statement

Bu çalışma için Fırat Üniversitesi Girişimsel Olmayan Araştırmalar Etik Kurulunun 10/02/2015 tarihli toplantısının 03 sayılı ve 02 numaralı kararınca etik kurul onayı alınmıştır.

Factors affecting serum S100B and neuron spesific enolase levels in cases of chronic migraine

Abstract

Abstract Objective: This study aimed to investigate whether there were increases in NSE and S100B levels, which indicate cellular damage in the brain in patients with chronic migraine, and if there were increases, whether there was a change in NSE and S100B levels compared to baseline along with clinical improvement after treatment. Method: Thirty individuals diagnosed with chronic migraine who presented to the Neurology Clinic of X University Hospital were included in the patient group, and 20 healthy volunteers were included in the control group. Patients with chronic migraine received a 3-month treatment with amitriptyline at a dose of 75 mg/day. Serum NSE and S100B levels were measured in the patient and control groups at the beginning of the study. Serum NSE and S100B levels were measured again in the patient group after 3 months of amitriptyline treatment. Findings: In this study, no statistically significant difference was found in S100B and NSE levels between the control group and the chronic migraine patient group. No statistically significant difference was observed in serum S100B and NSE levels before and after treatment in the chronic migraine patient group. However, correlation analysis revealed a weak, positive, and non-significant correlation between S100B and NSE levels before treatment. After treatment, this relationship became moderately positive and statistically significant. Conclusion: Based on the results of this study, monitoring S100B and NSE, believed to be markers of neuronal damage, may be useful in monitoring the effectiveness of treatment in chronic migraine patients, unlike in healthy individuals.

Keywords

• Chronic Migraine
• Neuron Specific Enolase
• S100B
• treatment response

Supporting Institution

Fırat Üniversitesi BAP

Ethical Statement

Bu çalışma için Fırat Üniversitesi Girişimsel Olmayan Araştırmalar Etik Kurulunun 10/02/2015 tarihli toplantısının 03 sayılı ve 02 numaralı kararınca etik kurul onayı alınmıştır.

References

1. Referans 1. Silberstein SD, Lipton RB, Goadsby PJ. Headache in Clinical Practice. London Isis Medical Media Pres. 1998: 1-67.
2. Referans 2. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
3. Referans 3. Vargas BB, Dodick DW. The face of chronic migraine: epidemiol ogy, demographics and treatment strategies. Neurol Clin. 2009; 27; 2: 467-479.
4. Referans 4. Langeh U, Singh S. Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders. Curr Neuropharmacol. 2021;19(2):265-277.
5. Referans 5. Hu J, Xie S, Xia W, Huang F, Xu B, Zuo Z, et al. Meta-analysis of evaluating neuron specific enolase as a serum biomarker for sepsis-associated encephalopathy. Int Immunopharmacol. 2024; 131:111857.
6. Referans 6. Azapagasi E, Alehan F, Saygi S, Bayraktar N, Yazici AC. Serum concentrations of neuron-specific enolase in pediatric migraine. Turk J Pediatr. 2012; 54: 150-155.
7. Referans 7. Yilmaz N, Karaali K, Ozdem S, Turkay M, Unal A, Dora B. Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: evidence for neurodegeneration? Cell Mol Neurobiol. 2011; 31: 579-585.
8. Referans 8. Teepker M, Munk K, Mylius V, Haag A, Möller JC, Oertel WH, et al. Serum concentrations of s100b and NSE in migraine. Headache. 2009; 49: 245-252.

9. Referans 9. Celikbilek A, Sabah S, Tanik N, Ak H, Atalay T, et al. Is serum S100B protein an useful biomarker in migraine? Neurol Sci. 2014(8): 1197-1201.
10. Referans 10. Yardan T, Erenler AK, Baydin A, Aydin K, Cokluk C. Usefulness of S100B protein in neurological disorders. J Pak Med Assoc. 2011; 61: 276-281.
11. Referans 11. Cho S, Chu MK. Serological Biomarkers of Chronic Migraine. Current Pain and Headache Reports. 2023; 27:531–542.
12. Referans 12. Johnsson P, Blomquist S, Luhrs C, Malmkvist G, Alling C, Solem JO, et al. Neuronspecific enolase increases in plasma during and immediately after extracorporeal circulation. Ann Thorac Surg. 2000; 69: 750-754.
13. Referans 13. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 1987; 10: 269-295.
14. Referans 14. Calcagnile O, Unden L, Unden J. Clinical validation of S100B use in management of mild head injury. BMC Emerg Med. 2012; 12: 13.
15. Referans 15. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003; 60: 540-551.
16. Referans 16. Yilmaz S. Serum NO, S100B, NSE concentrations in migraine and their relationship. J Clin Neurosci. 2020; 82(Pt A):32-35.
17. Referans 17. Gönen M, Özdoğan S, Balgetir F, Demir CF, Aytaç E, et al. S100B and neuron-specific enolase levels in episodic and chronic migraine. Acta Neurol Scand. 2021; 143(3):298-302.
18. Referans18. Chu C, Zhong R, Cai M, Li N, Lin W. Elevated Blood S100B Levels in Patients With Migraine: A Systematic Review and Meta-Analysis. Front Neurol. 2022,13: 914051.
19. Referans 19. Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care. 2007;6:121-138.
20. Referans 20. Derwall M, Stoppe C, Brucken D, Rossaint R, Fries M. Changes in S100 protein serum levels in survivors of out-of-hospital cardiac arrest treated with mild therapeutic hypothermia: a prospective, observational study. Crit Care. 2009;13(2):R58.
21. Referans 21. Riesco N, Cernuda-Morollon E, Martinez-Camblor P, Perez-Pereda S, Pascual J. Peripheral, interictal serum S100B levels are not increased in chronic migraine patients. Headache. 2020; 60:1705-1711.
22. Referans 22. Hafner A, Obermajer N, Kos J. γ-Enolase C-terminal peptide promotes cell survival and neurite outgrowth by activation of the PI3K/Akt and MAPK/ERK signalling pathways. Biochem J. 2012; 15;443(2):439-450.
23. Referans 23. Zheng J, Liang J, Deng X, Chen X, Wu F, Zhao X, et al. Mitogen activated protein kinase signaling pathways participate in the active principle region of Buyang Huanwu decoction-induced differentiation of bone marrow mesenchymal stem cells. Neural Regen Res. 2012;7(18):1370-1377.
24. Referans 24. Haque A, Polcyn R, Matzelle D, Banik NL. New Insights into the Role of Neuron-Specific Enolase in Neuro-Inflammation, Neurodegeneration, and Neuroprotection. Brain Sci. 2018;8(2):33.
25. Referans 25. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood–brain barrier damage. Clinical Chimica Acta. 2004; 342(1-2): 1-12.
26. Referans 26. Anderson TN, Hlatky R, Goodman JC. Serum S100B levels after exercise: a marker of CNS injury or peripheral release? Medicine and Science in Sports and Exercise. 2001; 33(3): 512-517.
27. Referans 27. Thelin EP, Jeppsson E, Frostell A, Svensson M, Bellander BM. S100B is an important biomarker for traumatic brain injury but not fully specific to the brain. Biomarkers. 2017; 22(7): 680-686.